Notice: Clarifications Regarding Access to Restricted Drugs through the Special Access Program (SAP)

Notice: Clarifications Regarding Access to Restricted Drugs through the Special Access Program (SAP) Drugs are authorized for sale in Canada once they have successfully gone through the drug review process, which includes the assessment of the safety, efficacy and quality of the drug. However, Health Canada's SAP allows practitioners to request access to drugs that are not available in Canada for the emergency treatment of patients with serious or life-threatening conditions who have exhausted other treatment options. 2021-12-29 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetynotice of clarificationsaccess to restricted-drugsSpecial Access ProgramSAPdrug review processaccess to drugsnot-available for emergency-treatmentlife-threatening conditionsother treatment options Notice: Clarifications Regarding Access to Restricted Drugs through the Special Access Program (SAP)HTML https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/notice-clarifications-regarding-restricted-drugs-program.html Notice: Clarifications Regarding Access to Restricted Drugs through the Special Access Program (SAP)HTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/acces-special/avis-clarifications-concernant-drogues-usage-restreint-biais-programme.html

Drugs are authorized for sale in Canada once they have successfully gone through the drug review process, which includes the assessment of the safety, efficacy and quality of the drug. However, Health Canada's SAP allows practitioners to request access to drugs that are not available in Canada for the emergency treatment of patients with serious or life-threatening conditions who have exhausted other treatment options.

Data and Resources

Similar records